If AI Can't Read Your Science, Investors Won't Either

By Holley Miller, founder and president, Grey Matter Marketing

AI is now embedded across the investment landscape — and life sciences is no exception. Across venture capital and private equity, firms are deploying AI-powered screening tools to sort through thousands of deals at once. The technology is impressive, but it's also early — and while investors work through the trial and error of algorithmic deal screening, most life sciences founders have no idea the audience for their pitch has changed. Life sciences founders who keep their story locked behind NDAs risk never making it past the first automated filter.

Many firms now rely on large language models (LLMs) to triage deal flow, such as scanning public materials and ranking opportunities before a human ever engages.

For founders who have spent years building transformative technology and pipelines in stealth, this shift carries a specific and underappreciated risk. If the machine can't read your story, you get skipped entirely. The smartest response is to design a commercial runway that forces capital to come to you.

The New Invisible Rejection

Silence from investors used to mean disinterest. In today’s world, it likely means you were never even seen.

Increasingly, the first filter is a model trained on a fund's investment mandate, crawling publicly available content to categorize and prioritize opportunities before anyone on the investment team reads a word.

The first decision about your company is now made at machine speed by an LLM before a human ever engages. But these systems are limited in ways that matter enormously for novel healthcare technologies. LLM agents work from available text. They evaluate what's written, and they can identify companies that fit neatly into a box. They don’t reward novelty. They reward pattern recognition.

The more novel the science, the more likely it falls outside the pattern these models are trained to recognize.

When Stealth Means Invisible

Stealth used to signal discipline, but now, it often signals absence. Regulatory timelines are long and the instinct to keep details locked behind NDAs is rational.

The new investor funnel doesn’t reward differentiation. It rewards what’s legible. When the only publicly available content about your company is a vague website and a handful of conference abstracts, the algorithmic layer of the capital market has nothing to work with.

Founders can protect their IP and still give the market enough signal to work with. The key is being strategic about what you make visible and how you frame it. A clear, commercially grounded description of the problem you solve, the stakeholders whose behavior must change, and the market conditions that make your solution necessary will do more to attract the right investors than another round of stealth mode mystique.

The Audience Founders Forget

Most CEOs still build their narrative around the product. They lead with mechanisms of action, clinical endpoints, and technical differentiation. However, this speaks to only one audience — and that’s not the one that determines adoption.

Adoption in healthcare is never a single decision. It’s a coordinated belief shift:

• Clinicians must reject the current standard.
• Payers must see reimbursement viability.
• Health systems must accept workflow disruption.

LLM screening tools are especially weak in this territory. They can map competitive landscapes, but they can't model the belief shifts required for a new category to take hold.

This particular gap is where founders need to do their own storytelling. CEOs who can articulate the behavior change their product requires — and demonstrate a strategy for engineering that change — separate themselves from every company whose pitch reads like a feature comparison.

Designing A Runway That Outlasts The Funding Cycle

The founders who win in this environment don’t rely on access to capital. They make themselves unavoidable. The focus should be on early revenue and real-world validation — signals that matter more than projections.

It also means looking beyond the traditional venture path. Non-dilutive capital through grants, SBIR/STTR programs, strategic partnerships, and joint ventures can extend runway without surrendering equity at unfavorable terms. Family offices and sovereign wealth funds carry longer time horizons and different risk tolerances than traditional VCs, making them natural partners for deep-science companies whose value accrues over years rather than quarters.

Legibility As Strategy

Legibility isn’t a marketing exercise. It’s a strategic requirement.

Your external assets, such as websites, published talks, white papers, and case studies, need to define the category you're creating and frame the problem in ways the market hasn't seen before.

If you describe your company in an existing category, you guarantee you’ll be evaluated on incumbent terms. The companies that break through, however, give the market a new way to understand the problem. They define the cost of the status quo, name the gap, and make their solution the inevitable outcome.

Building For Durability

Algorithmic investor screening changes the mechanics of how deals get sourced and sorted. It does not change the fundamentals of what makes healthcare companies durable. Clinical impact, market belief, stakeholder behavior change, and commercial traction still determine which companies survive and which scale.

Founders who understand their real audiences and build resilient runways through diversified capital will control the terms of their future fundraising. If the market can’t understand you, it can’t fund you. And now, it may never even find you.

About The Author

Holley Miller is founder and president of Grey Matter Marketing, the first healthcare category design firm. She spent her early career in product development, communications, and commercialization at companies including Allergan and Intuitive Surgical, where she watched the same pattern repeat: strong innovation that didn't translate into adoption. She founded Grey Matter in 2006 to solve one of the hardest problems in life sciences, helping CEOs, boards, and investors close the gap between a product that works and a market that embraces it. Her work has contributed to more than $4.5 billion in enterprise value created.